Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.
Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.
April 11, 2019 at 12:00 PM EDT
MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc.(Nasdaq: CMTA) (“Clementia” or the “Corporation”) is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement under the Canada Business Corporations Act pursuant to which a wholly-owned subsidiary of Ipsen S.A. will acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share in cash upfront on completion of the transaction plus a deferred payment on the achievement of a future regulatory milestone in the form of a contingent value right of US$6.00 per share payable upon the U.S. Food and Drug Administration’s (FDA) acceptance of submission of a new drug application (NDA) filing for palovarotene for the treatment of multiple osteochondromas (MO) on or prior to December 31, 2024.
Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.
April 11, 2019 at 12:00 PM EDT
MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc.(Nasdaq: CMTA) (“Clementia” or the “Corporation”) is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement under the Canada Business Corporations Act pursuant to which a wholly-owned subsidiary of Ipsen S.A. will acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share in cash upfront on completion of the transaction plus a deferred payment on the achievement of a future regulatory milestone in the form of a contingent value right of US$6.00 per share payable upon the U.S. Food and Drug Administration’s (FDA) acceptance of submission of a new drug application (NDA) filing for palovarotene for the treatment of multiple osteochondromas (MO) on or prior to December 31, 2024.
Related Press Releases

IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023

Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England...

IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023

Ipsen updates on QM-1114 regulatory process

IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023

Ipsen nominates Pascal Touchon to its Board of Directors as new independent director

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
